Web developed by Bolinger web design
- June 5th, 2013 - Data Released at ASCO Demonstrates the Severe Unmet Need in ...
- June 4th, 2013 - Rockwell Medical Announces Completion of Dosing for Phase II...
- May 31st, 2013 - LifeSci Advisors Outstanding 2013 ASCO Abstracts...
- May 30th, 2013 - Anthera Announces First Quarter Financial Results and Provid...
- May 21st, 2013 - Rockwell Medical Completes Financing; now Fully-funded Throu...
- May 21st, 2013 - TiGenix Announces Q1 2013 Results
- May 15th, 2013 - Ablynx Announces Quarterly Results and Corporate Update...
- May 14th, 2013 - LIFESCI ADVISORS INITIATES COVERAGE OF PROTHENA CORPORATION...
- May 9th, 2013 - Celsus Announces Interim Phase II Data for MRX-6 to Treat Al...
- May 6th, 2013 - LIFESCI ADVISORS INITIATES COVERAGE OF LIPOCINE INC...
- April 29th, 2013 - LifeSci Advisors Initiates Coverage of BrainStorm Cell Thera...
- April 29th, 2013 - TiGenix Releases Positive Phase IIa Results Using Allogeneic...
- April 15th, 2013 - Innate Pharma Presents New Data at Two Conferences Highlight...
- April 10th, 2013 - DelMar Pharmaceuticals Announces Encouraging Phase I-II GBM ...
- April 8th, 2013 - LifeSci Advisors Initiates Coverage of Celsus Therapeutics...
- April 2nd, 2013 - LifeSci Advisors Initiates Coverage of Adocia...
- March 28th, 2013 - ARM Investor Day
- March 27th, 2013 - NAVB: FDA Approves Lymphoseek, First Patient Enrolled in Pha...
- March 21st, 2013 - BrainStorm Releases Phase I/II Results for ALS at AAN...
- March 20th, 2013 - TiGenix Announces 2012 Fiscal Year Results...
- March 19th, 2013 - Ablynx Completes €31.5 Million Private Placement...
- March 13th, 2013 - DelMar Pharmaceuticals Becomes Public Through Reverse Merger...
- March 7th, 2013 - RXi Pharmaceuticals Announces Pooling of RNAi Assets with OP...
- March 6th, 2013 - LifeSci Advisors Initiates Coverage of Ampio Pharmaceuticals...
- March 5th, 2013 - Acthar Gel Rheumatologists Survey
- March 5th, 2013 - LIFESCI ADVISORS INITIATES COVERAGE ON ADHEREX TECHNOLOGIES...
- February 28th, 2013 - Anthera Announces Clinical Path for Blisibimod – Phase...
- February 14th, 2013 - Ablnyx Announces 24-Week Results from the ALX-0061 Phase II ...
- February 14th, 2013 - Exciting Scar Reduction Activity Observed in Two Phase 1 RXI...
- February 13th, 2013 - PRIME Data Shows SFP Achieves 37% ESA Sparing; Meets Primary...
- February 11th, 2013 - LIFESCI ADVISORS INITIATES COVERAGE OF NAVIDEA BIOPHARMACEUT...
- January 29th, 2013 - The Company has announced dosing of the first patient of a P...
- January 5th, 2013 - Anthera to host Event at 2013 JP Morgan Healthcare Conferenc...
- January 3rd, 2013 - Ablynx 2012 Recap
- January 3rd, 2013 - LIFESCI ADVISORS INITIATES COVERAGE OF TIGENIX, NV...
- December 19th, 2012 - LIFESCI ADVISORS INITIATES COVERAGE OF CYTOMEDIX, INC....
- November 28th, 2012 - LIFESCI ADVISORS INITIATES COVERAGE OF RXI PHARMACEUTICALS...
- November 26th, 2012 - Ablynx Announces Research Collaboration With Algeta to Explo...
- November 5th, 2012 - Agreement Upgraded to Collaboration – Del Mar Now Has Worl...
- November 1st, 2012 - IPH.PA: Phase 1 IPH21/Anti-PD1 Combo Study in Solid Tumors A...
- October 31st, 2012 - More Positive PEARL-SC Data; Anthera Moves Blisibimod Into P...
- October 18th, 2012 - Innate Pharma Announces Positive IPH21 Phase 1 AML Trial Res...
- October 9th, 2012 - Veloxis Announces Strategic Agreement for Commercialization ...
- October 8th, 2012 - Proof-of-Concept ALX-0061 RA Data and Potential €448MM Mer...
- October 8th, 2012 - LifeSci Advisors Publishes Recent Physician Survey on Questc...
- October 4th, 2012 - Our Valuation Suggests Innate Pharma is Undervalued...
- October 2nd, 2012 - A.P. Pharma Submits the APF530 NDA as Expected...
- September 20th, 2012 - Navidea’s Path to Lymphoseek CRL Response Not as Complicat...
- September 20th, 2012 - Rockwell Medical is a Low-Risk, High-Reward Investment in th...
- September 18th, 2012 - First Inhaled Nanobody Achieves Proof-of-Concept with Succes...
LifeSci Advisors is a unique consultancy founded to provide comprehensive equity research, strategic counsel, customized marketing communications and investor relations services to our clients in the life-sciences.
Advisory
- Financial Transaction Support
- Business Development Activities
- Market Research
Investor Relations
- Non-deal Roadshows
- Industry Meeting Support
- Media Relations
Equity Research
- Detailed Initiation Reports
- Event-driven Updates
- Expert Conference Calls
Web developed by Bolinger web design
